仙灵骨葆胶囊对骨质疏松症患者骨密度和血清Ⅰ型胶原羧基末端交联肽、N端中段骨钙素、骨钙素的影响

摘要

目的：探讨仙灵骨葆胶囊对骨质疏松症患者骨密度和血清Ⅰ型胶原羧基末端交联肽（β-CTX）、N端中段骨钙素（ N-MID）、骨钙素（ BGP）的影响。方法：采用随机对照研究，选取符合纳入标准的骨质疏松症患者50例，以随机数字表法分为观察组和对照组，每组各25例。对照组患者应用抗骨质疏松基础用药治疗，观察组患者在对照组基础上联合应用仙灵骨葆胶囊，8周为1个疗程。观察治疗前和治疗6、12个月后2组患者骨密度、血清β-CTX、N-MID、BGP水平变化情况。结果：治疗12个月后，观察组患者腰椎正位（L2-4）、左股骨颈的骨密度均明显高于对照组，差异均有统计学意义（P＜0.05）。治疗12个月后，观察组患者血清β-CTX水平较治疗前明显降低，且明显低于对照组治疗12个月后，差异均有统计学意义（P＜0.05）；治疗6、12个月后，2组患者血清N-MID水平与治疗前的差异无统计学意义（ P＞0.05）；治疗6、12个月后，观察组患者血清BGP水平均较治疗前明显升高，且分别明显高于对照组治疗6、12个月后，差异均有统计学意义（ P＜0.05）。结论：仙灵骨葆胶囊与抗骨质疏松基础用药联合治疗，能显著改善骨质疏松症患者骨密度状况，并能显著降低血清β-CTX水平、升高血清BGP水平，但对血清N-MID的影响作用甚微。%OBJECTIVE:To probe into the effects of Xianlinggubao capsules on bone mineral density , serumβ-CTX, N-MID and BGP in osteoporosis patients .METHODS:Randomized controlled trials ( RCT ) were adopted , 50 osteoporosis patients were extracted to be divided into observation group and control group via the random number table , with 25 cases in each.The control group were treated with basic medicine , while the observation group were additionally treated with Xianlinggubao capsules based on the control group , the treatment course was 8 weeks.The bone mineral density, serumβ-CTX, N-MID and BGP level before treatment and after treatment of 6 and 12 months.RESULTS: After treatment of 12 months, the BMD of anterial position of lumbar spine ( L2-4 ) and left neck of femur in observation group were higher than those in control group, with statistically significant difference(P0.05).And the serum BGP level of observation group was higher than that of before treatment , and was respectively higher than that of control group after treatment of 6 and 12 months, with statistically significant difference(P<0.05).CONCLUSIONS:Xianlinggubao capsules combined with basic medicine can effectively improve the BMD in osteoporosis patients , and significantly reduce serum β-CTX level , increasing BGP level;yet it has few effects on N-MID.